中文

Journal of Shanghai University >

2018 , Vol. 24 >Issue 2: 192 - 197

DOI: https://doi.org/10.12066/j.issn.1007-2861.2015

Precision and Translational Medicine

Qiliqiangxin attenuates doxorubicin induced cardiac dysfunction in mice

Expand
  • 1. Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
    2. Clinical Laboratory Center, Beijing Hospital of Traditional Chinese Medicine, Beijing 100010, China

Received date: 2018-03-07

  Online published: 2018-05-07

Fold

Abstract

To investigate the therapeutic effects of Qiliqiangxin (QLQX) in doxorubicin (DOX)-induced cardiac dysfunction in vivo. Male mice aged 7~9 weeks were randomly divided into several groups. DOX (4 mg/kg) was injected to induce cardiotoxicity via intraperitoneal administration weekly, and QLQX was given by gavage every day for 4 weeks at a dose of 0.5 g/(kg$\cdot$d). After 4 weeks, echocardiography was performed to detect the cardiac function and it was showed that cardiac function could be significantly improved in mice treated with QLQX versus the saline. These findings indicated that QLQX could function as an intervening treatment for the patients who were treated with DOX.

Key words： Qiliqiangxin (QLQX); doxorubicin (DOX); cardiotoxicity; mitochondria

Cite this article

WU Xiaodong, JIANG Huimin, YAO Wenming, GAO Rongrong, LI Xinli . Qiliqiangxin attenuates doxorubicin induced cardiac dysfunction in mice[J]. Journal of Shanghai University, 2018 , 24(2) : 192 -197 . DOI: 10.12066/j.issn.1007-2861.2015

References

[1] Carvalho F S, Burgeiro A, Garcia R, et al. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy[J]. Medicinal Research Reviews, 2014,34:106-135.
[2] Arif I S, Hooper C L, Greco F, et al. Increasing doxorubicin activity against breast cancer cells using PPARgamma-ligands and by exploiting circadian rhythms[J]. British Journal of Pharmacology, 2013,169:1178-1188.
[3] Zhao L, Qi Y, Xu L, et al. MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting nrf2 and sirt2[J]. Redox Biology, 2018,15:284-296.
[4] Li S, Wang W, Niu T, et al. Nrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction[J]. Oxid Med Cell Longev, 2014,2014:748524.
[5] Steinherz L J, Steinherz P G, Tan C, et al. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients[J]. Pediatric Blood & Cancer, 1995,24(6):352.
[6] Cappetta D, De Angelis A, Sapio L, et al. Oxidative stress and cellular response to doxorubicin: a common factor in the complex milieu of anthracycline cardiotoxicity[J]. Oxid Med Cell Longev, 2017(16):1521020.
[7] Fernandez-Chas M, Curtis M J, Niederer S A. Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model[J]. British Journal of Pharmacology, 2017, DOI: 10.1111/bph.14104.
[8] Li M S V, De Santis M C, Cimino J, et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth[J]. Circulation, 2018, DOI: 10.1161/CIRCULATIONAHA.117.030352.
[9] Yuan Y P, Ma Z G, Zhang X, et al. Ctrp3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of sirt1[J]. Journal of Molecular and Cellular Cardiology, 2018,114:38-47.
[10] Tony H, Yu K, Qiu T Z. MicroRNA-208a silencing attenuates doxorubicin induced myocyte apoptosis and cardiac dysfunction[J]. Oxid Med Cell Longev, 2015(17):597032.
[11] Tao L, Shen S, Fu S, et al. Traditional Chinese medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice[J]. Scientific Reports, 2015, DOI: 10.1038/srep08374.
[12] Lin S, Wu X, Tao L, et al. The metabolic effects of traditional Chinese medication Qiliqiangxin on h9c2 cardiomyocytes[J]. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 2015,37:2246-2256.
[13] Zhang J, Wei C, Wang H, et al. Protective effect of Qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats[J]. Evidence-Based Complementary and Alternative Medicine, 2013,2013:378298.
[14] Yarana C, Carroll D, Chen J, et al. Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury[J]. Clinical Cancer Research, 2017, DOI: 10.1158/1078-0432.CCR-17-2046.
[15] Khiati S, Dalla Rosa I, Sourbier C, et al. Mitochondrial topoisomerase 1 (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity[J]. Clinical Cancer Research, 2014,20:4873-4881.
Options
Outlines

/

〈 〉